Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs (Q34107607)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

11

object named as

Nayoung Kim

1 reference

Europe PubMed Central

31 July 2017

Sook-Hyang Jeong

10

object named as

Sook-Hyang Jeong

1 reference

Europe PubMed Central

31 July 2017

author name string

Hyung Rae Sohn

1

1 reference

Europe PubMed Central

31 July 2017

Bo Young Min

2

1 reference

Europe PubMed Central

31 July 2017

Joon Chang Song

3

1 reference

Europe PubMed Central

31 July 2017

Mun Hyuk Seong

4

1 reference

Europe PubMed Central

31 July 2017

Sang Soo Lee

5

1 reference

Europe PubMed Central

31 July 2017

Eun Sun Jang

6

1 reference

Europe PubMed Central

31 July 2017

Cheol Min Shin

7

1 reference

Europe PubMed Central

31 July 2017

Young Soo Park

8

1 reference

Europe PubMed Central

31 July 2017

Jin-Hyeok Hwang

9

1 reference

Europe PubMed Central

31 July 2017

Dong Ho Lee

12

1 reference

Europe PubMed Central

31 July 2017

Jin-Wook Kim

13

1 reference

Europe PubMed Central

31 July 2017

publication date

13 August 2014

1 reference

Europe PubMed Central

31 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

31 July 2017

14

1 reference

Europe PubMed Central

31 July 2017

439

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2334-14-439

0 references

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Implementation of Consolidated HIS: Improving Quality and Efficiency of Healthcare.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Chronic hepatitis B: update 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148928

5 July 2018

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-439

21 January 2018

Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25125320

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-14-439

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34107607&oldid=1956560729"